Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Effect of antimicrobial stewardship with rapid MALDI-TOF identification and Vitek 2 antimicrobial susceptibility testing on hospitalization outcome.

Cavalieri SJ, Kwon S, Vivekanandan R, Ased S, Carroll C, Anthone J, Schmidt D, Baysden M, Destache CJ.

Diagn Microbiol Infect Dis. 2019 Jun 6. pii: S0732-8893(19)30304-9. doi: 10.1016/j.diagmicrobio.2019.05.020. [Epub ahead of print]

PMID:
31279585
2.

Correction to: Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.

Prathipati PK, Mandal S, Pon G, Vivekanandan R, Destache CJ.

Pharm Res. 2019 May 20;36(7):108. doi: 10.1007/s11095-019-2638-z.

PMID:
31111294
3.

Corrigendum to "Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission" [Journal of Controlled Release 294 (2019) 216-225].

Mandal S, Kang G, Prathipati PK, Zhou Y, Fan W, Li Q, Destache CJ.

J Control Release. 2019 Jun 28;304:101. doi: 10.1016/j.jconrel.2019.05.002. Epub 2019 May 10. No abstract available.

PMID:
31082646
4.

A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study.

Mandal S, Prathipati PK, Belshan M, Destache CJ.

Antiviral Res. 2019 Jul;167:83-88. doi: 10.1016/j.antiviral.2019.04.007. Epub 2019 Apr 13.

PMID:
30991088
5.

A review of CCR5 antibodies against HIV: current and future aspects.

Prathipati PK, Mandal S, Destache CJ.

Ther Deliv. 2019 Feb;10(2):107-112. doi: 10.4155/tde-2018-0072.

PMID:
30729884
6.

Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience.

Destache CJ, Guervil DJ, Kaye KS.

Int J Antimicrob Agents. 2019 May;53(5):644-649. doi: 10.1016/j.ijantimicag.2019.01.014. Epub 2019 Jan 31.

7.

Indole-2-Carboxamides Are Active against Mycobacterium abscessus in a Mouse Model of Acute Infection.

Pandya AN, Prathipati PK, Hegde P, Li W, Graham KF, Mandal S, Drescher KM, Destache CJ, Ordway D, Jackson M, North EJ.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02245-18. doi: 10.1128/AAC.02245-18. Print 2019 Mar.

PMID:
30602519
8.

Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.

Mandal S, Kang G, Prathipati PK, Zhou Y, Fan W, Li Q, Destache CJ.

J Control Release. 2019 Jan 28;294:216-225. doi: 10.1016/j.jconrel.2018.12.027. Epub 2018 Dec 18. Erratum in: J Control Release. 2019 Jun 28;304:101.

PMID:
30576746
9.

Development and validation of LC-MS/MS method for quantification of bictegravir in human plasma and its application to an intracellular uptake study.

Prathipati PK, Mandal S, Destache CJ.

Biomed Chromatogr. 2019 Feb;33(2):e4379. doi: 10.1002/bmc.4379. Epub 2018 Oct 9.

PMID:
30178512
10.

Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study.

Mandal S, Kang G, Prathipati PK, Fan W, Li Q, Destache CJ.

Antiviral Res. 2018 Aug;156:85-91. doi: 10.1016/j.antiviral.2018.06.005. Epub 2018 Jun 6.

PMID:
29885378
11.

LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine in dried blood spots.

Prathipati PK, Mandal S, Destache CJ.

Biomed Chromatogr. 2018 Apr 26:e4270. doi: 10.1002/bmc.4270. [Epub ahead of print]

PMID:
29700852
12.

Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening.

Pattnaik A, Palermo N, Sahoo BR, Yuan Z, Hu D, Annamalai AS, Vu HLX, Correas I, Prathipati PK, Destache CJ, Li Q, Osorio FA, Pattnaik AK, Xiang SH.

Antiviral Res. 2018 Mar;151:78-86. doi: 10.1016/j.antiviral.2017.12.016. Epub 2017 Dec 21.

PMID:
29274845
13.

Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.

Holec AD, Mandal S, Prathipati PK, Destache CJ.

Curr HIV Res. 2017;15(6):411-421. doi: 10.2174/1570162X15666171120110145. Review.

PMID:
29165087
14.

Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.

Prathipati PK, Mandal S, Pon G, Vivekanandan R, Destache CJ.

Pharm Res. 2017 Dec;34(12):2749-2755. doi: 10.1007/s11095-017-2255-7. Epub 2017 Sep 13. Erratum in: Pharm Res. 2019 May 20;36(7):108.

15.

Evaluation of Staphylococcus aureus Bacteremia: Academic and Community-Based Management Within the Same Health System.

Ased S, Rayes H, Dhami J, Amosson N, Fordjour A, Macaraeg J, Vivekanandan R, Wilson J, Cabri A, Davids M, Anthone J, Cavalieri S, Destache CJ.

Infect Control Hosp Epidemiol. 2017 Jun;38(6):740-742. doi: 10.1017/ice.2017.30. Epub 2017 Mar 15.

PMID:
28294090
16.

Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.

Mandal S, Prathipati PK, Kang G, Zhou Y, Yuan Z, Fan W, Li Q, Destache CJ.

AIDS. 2017 Feb 20;31(4):469-476. doi: 10.1097/QAD.0000000000001349. Erratum in: AIDS. 2019 Jul 15;33(9):1543.

17.

Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.

Khandalavala K, Mandal S, Pham R, Destache CJ, Shibata A.

J Nanotechnol Mater Sci. 2017;4(2):53-61. doi: 10.15436/2377-1372.17.1583. Epub 2017 Aug 7.

18.

An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.

Mandal S, Belshan M, Holec A, Zhou Y, Destache CJ.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01475-16. doi: 10.1128/AAC.01475-16. Print 2017 Jan.

19.

Education and Communication in an Interprofessional Antimicrobial Stewardship Program.

Foral PA, Anthone JM, Destache CJ, Vivekanandan R, Preheim LC, Gorby GL, Horne JM, Dobronski LA, Syed JJ, Mindru C, Ali MA, Ali KF, Neemann KA, Bittner MJ.

J Am Osteopath Assoc. 2016 Sep 1;116(9):588-93. doi: 10.7556/jaoa.2016.116.

PMID:
27571295
20.

Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.

Prathipati PK, Mandal S, Destache CJ.

J Pharm Biomed Anal. 2016 Sep 10;129:473-481. doi: 10.1016/j.jpba.2016.07.040. Epub 2016 Jul 26.

21.

Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.

Destache CJ, Mandal S, Yuan Z, Kang G, Date AA, Lu W, Shibata A, Pham R, Bruck P, Rezich M, Zhou Y, Vivekanandan R, Fletcher CV, Li Q.

Antimicrob Agents Chemother. 2016 May 23;60(6):3633-9. doi: 10.1128/AAC.00450-16. Print 2016 Jun.

22.

Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis.

Anantha Narayanan M, Mahfood Haddad T, Kalil AC, Kanmanthareddy A, Suri RM, Mansour G, Destache CJ, Baskaran J, Mooss AN, Wichman T, Morrow L, Vivekanandan R.

Heart. 2016 Jun 15;102(12):950-7. doi: 10.1136/heartjnl-2015-308589. Epub 2016 Feb 11. Review.

PMID:
26869640
23.

Natural polyphenols: potential in the prevention of sexually transmitted viral infections.

Date AA, Destache CJ.

Drug Discov Today. 2016 Feb;21(2):333-41. doi: 10.1016/j.drudis.2015.10.019. Epub 2015 Nov 4. Review.

PMID:
26546859
24.

Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.

Kovarova M, Council OD, Date AA, Long JM, Nochi T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV.

PLoS Pathog. 2015 Oct 16;11(10):e1005170. doi: 10.1371/journal.ppat.1005170. eCollection 2015 Oct. No abstract available.

25.

Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.

Date AA, Shibata A, McMullen E, La Bruzzo K, Bruck P, Belshan M, Zhou Y, Destache CJ.

J Biomed Nanotechnol. 2015 Mar;11(3):416-27.

26.

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.

Kovarova M, Council OD, Date AA, Long JM, Nochi T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV.

PLoS Pathog. 2015 Aug 13;11(8):e1005075. doi: 10.1371/journal.ppat.1005075. eCollection 2015 Aug. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005170. Nochii, Tomonori [corrected to Nochi, Tomonori].

27.
28.

Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.

Li Q, Tso FY, Kang G, Lu W, Li Y, Fan W, Yuan Z, Destache CJ, Wood C.

J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):519-27. doi: 10.1097/QAI.0000000000000687.

29.

Direct differentiation of adult ocular progenitors into striatal dopaminergic neurons.

Ahmad I, Zhao X, Parameswaran S, Destache CJ, Rodriguez-Sierra J, Thoreson WB, Ahmad H, Sorrentino J, Balasubramanian S.

Int J Stem Cells. 2015 May;8(1):106-14. doi: 10.15283/ijsc.2015.8.1.106.

30.

Hepatitis C therapy: Looking toward interferon-sparing regimens.

Au TH, Destache CJ, Vivekanandan R.

J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):e72-84; quiz e85-6. doi: 10.1331/JAPhA.2015.15508. Review.

PMID:
25658389
31.

Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates.

Date AA, Shibata A, Bruck P, Destache CJ.

Biomed Chromatogr. 2015 May;29(5):709-15. doi: 10.1002/bmc.3346. Epub 2014 Oct 9.

32.

Breaking down the barriers: challenges with development and implementation of an industry-sponsored antimicrobial stewardship data collection and analysis tool.

Hermsen ED, McDaneld PM, Eiland EH 3rd, Destache CJ, Lusardi K, Estrada SJ, Mercier RC, DePestel DD, Lamp KC, Anderson E, Chung TJ, McKinnon PS.

Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S179-84. doi: 10.1093/cid/ciu539.

PMID:
25261545
33.

Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter.

DePestel DD, Eiland EH 3rd, Lusardi K, Destache CJ, Mercier RC, McDaneld PM, Lamp KC, Chung TJ, Hermsen ED.

Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S154-61. doi: 10.1093/cid/ciu548.

PMID:
25261542
34.

Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature.

Destache CJ.

J Pharm Pract. 2014 Dec;27(6):562-6. doi: 10.1177/0897190014546102. Epub 2014 Aug 14. Review.

PMID:
25124375
35.

Antimicrobial treatment of asymptomatic bacteriuria in noncatheterized adults: a systematic review.

Dull RB, Friedman SK, Risoldi ZM, Rice EC, Starlin RC, Destache CJ.

Pharmacotherapy. 2014 Sep;34(9):941-60. doi: 10.1002/phar.1437. Epub 2014 May 7. Review.

PMID:
24807583
36.

A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Date AA, Destache CJ.

Biomaterials. 2013 Aug;34(26):6202-28. doi: 10.1016/j.biomaterials.2013.05.012. Epub 2013 May 28. Review.

37.

Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.

Shibata A, McMullen E, Pham A, Belshan M, Sanford B, Zhou Y, Goede M, Date AA, Destache CJ.

AIDS Res Hum Retroviruses. 2013 May;29(5):746-54. doi: 10.1089/AID.2012.0301. Epub 2013 Feb 1. Erratum in: AIDS Res Hum Retroviruses. 2013 Jul;29(7):1095. Date, Abjijit A [corrected to Date, Abhijit A].

38.

Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.

Date AA, Shibata A, Goede M, Sanford B, La Bruzzo K, Belshan M, Destache CJ.

Antiviral Res. 2012 Dec;96(3):430-6. doi: 10.1016/j.antiviral.2012.09.015. Epub 2012 Oct 3.

39.

Teaching heart failure treatment guidelines and assessing heart failure therapy.

Packard KA, Lenz TL, Destache CJ.

Am J Pharm Educ. 2010 Aug 10;74(6):103.

40.

Antiretroviral nanoparticles: an extended drug delivery modality.

Destache CJ, Goede M, Belgum T.

Ther Deliv. 2010 Sep;1(3):383-6.

PMID:
22816141
41.

Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA.

J Antimicrob Chemother. 2010 Oct;65(10):2183-7. doi: 10.1093/jac/dkq318. Epub 2010 Aug 21.

42.

A survey of pharmacy students' experiences with gambling.

Elsasser GN, Kavan MG, Westerman GH, Destache CJ, Sexson E, Turner PD.

Am J Pharm Educ. 2010 Mar 10;74(2):26.

43.

Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A.

BMC Infect Dis. 2009 Dec 9;9:198. doi: 10.1186/1471-2334-9-198.

44.

Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.

Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE.

J Immunol. 2009 Jul 1;183(1):661-9. doi: 10.4049/jimmunol.0900274. Epub 2009 Jun 17.

45.

Role of prostanoid production and receptors in the regulation of retinal endogenous amino acid neurotransmitters by 8-isoprostaglandin E2, ex vivo.

Zhao M, Destache CJ, Ohia SE, Opere CA.

Neurochem Res. 2009 Dec;34(12):2170-80. doi: 10.1007/s11064-009-0013-x.

PMID:
19513831
46.

National survey of volunteer pharmacy preceptors.

Skrabal MZ, Jones RM, Nemire RE, Boyle CJ, Assemi M, Kahaleh AA, Soltis DA, Allen RE, Hritcko PM, O'Sullivan TA, Destache CJ.

Am J Pharm Educ. 2008 Oct 15;72(5):112.

47.

Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option.

Destache CJ.

Prog Brain Res. 2009;180:225-33. doi: 10.1016/S0079-6123(08)80012-X. Epub 2009 Dec 8. Review.

PMID:
20302837
48.

Regulation of retinal morphology and posterior segment amino acids by 8-isoprostaglandin E2 in bovine eyes ex vivo.

Zhao M, Destache CJ, Zhan G, Liu H, Zhang Y, Govindarajan V, Opere CA.

Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):615-26. doi: 10.1358/mf.2008.30.8.1268857.

PMID:
19088946
49.

Nanotechnology: a focus on nanoparticles as a drug delivery system.

Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ.

J Neuroimmune Pharmacol. 2006 Sep;1(3):340-50. Review.

PMID:
18040810
50.

Preprinted risk assessment and prophylaxis order form for venous thromboembolism.

Elsasser GN, Goodman MD, Destache CJ, Frey DR, Hadi Z.

Am J Health Syst Pharm. 2007 Jun;64(12):1294-8. No abstract available.

PMID:
17563053

Supplemental Content

Loading ...
Support Center